Vanda Pharmaceuticals, Inc. (VNDA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Vanda Pharmaceuticals, Inc. (VNDA)
Go deeper and ask any question about VNDA
Company Performance
Current Price
as of Sep 13, 2024$5.10
P/E Ratio
N/A
Market Cap
$297.28M
Description
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Metrics
Overview
- HQWashington, DC
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerVNDA
- Price$5.1+2.20%
Trading Information
- Market Cap$297.28M
- Float94.69%
- Average Daily Volume (1m)454,488
- Average Daily Volume (3m)684,926
- EPS-$0.19
Company
- Revenue$182.02M
- Rev Growth (1yr)9.59%
- Net Income-$4.52M
- Gross Margin91.11%
- EBITDA Margin-16.20%
- EBITDA-$8.18M
- EV-$50.30M
- EV/Revenue-0.28
- P/EN/A
- P/S1.63
Documents
SEC Filings
Earnings Calls